Zhao JZ, Ruzieh M, Du F, Lian Y, Foy AJ, Platt RW, et al
A prespecified analysis of the SELECT trial examined the relationship between changes in adiposity measures (body weight and waist circumference) and cardiovascular outcomes among 17,604 patients with obesity or overweight and established cardiovascular disease but without diabetes.[1] The analysis revealed that cardiovascular outcomes were similar among semaglutide-treated patients who did or did not lose at least 5% of their baseline body weight, and that semaglutide consistently reduced major adverse cardiovascular events across the full spectrum of baseline body mass index values
Glucose levels were determined in blood samples before (0) and at 15, 30, 60, and 120 min following glucose administration
Drugs with miraculous benefits require very few patients to meet bars for statistical significance
The acetylation-modulating capacity of butyrate positions it as a promising therapeutic candidate in treating cancer, inflammation, and neurological diseases (Table 1)
